Toujeo Max Injection, Solution
Product Images NDC 0024-5871

51 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 51 technical images submitted to the FDA as part of the official labeling for Toujeo Max (NDC 0024-5871). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (C9561d96 124d 48ca 982f 0aa1575bff36 01)

Figure 1 (C9561d96 124d 48ca 982f 0aa1575bff36 01)
A line graph depicting the glucose infusion rate (GIR) in mg/kg/min over time in hours following subcutaneous injection. The graph shows the GIR response for TOUJEO at a dose of 0.4 units/kg, with values plotted from 0 to 36 hours after injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 02)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 02)
An anatomical illustration showing common subcutaneous injection sites for insulin. Highlighted areas on the human figure include the upper arms, stomach, and thighs, indicating preferred locations for insulin glargine injection such as with TOUJEO Max 300 U/mL.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 03)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 03)
An instructional diagram of the TOUJEO Max insulin glargine injection pen, 300 units/mL, by Sanofi-Aventis. It labels key parts of the pen including the pen cap, cartridge holder, rubber seal, insulin scale, plunger, dose window, dose pointer, dose selector, and injection button. The label on the pen indicates it is for single use.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 04)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 04)
TOUJEO Max 300 Units/mL injection pen label for insulin glargine subcutaneous injection. The label indicates it is for single patient use only and shows the strength of 300 Units/mL. The pen is a prefilled solution device by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 05)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 05)
TOUJEO Max (insulin glargine) injection, solution, 300 U/mL, shown as an injection pen with a white body and green cap. The label includes a lot number and expiration date area, but specific lot and expiration details are obscured in the image. The product is by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 06)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 06)
An instructional illustration depicting hands preparing a TOUJEO Max insulin glargine injection pen. The left image shows a hand holding the pen with the dosage window displaying insulin units. The right image shows the hand pushing the injection button forward, indicated by a blue arrow, demonstrating the injection process.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 07)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 07)
An illustration showing a close-up cross-section of a TOUJEO Max insulin glargine injection pen. The image highlights the inner component where the insulin solution is contained within the pen cartridge, depicting its structure relevant to subcutaneous injection delivery.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 08)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 08)
An instructional illustration showing two hands handling an insulin cartridge or pen. One hand holds the pen, while the other hand is peeling off a protective paper or covering from the pen tip, indicating preparation for injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 09)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 09)
An instructional illustration showing two hands removing the cap from a small vial or ampule, likely part of a medication administration process related to the product.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 10)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 10)
An instructional illustration showing how to prepare and use the TOUJEO Max insulin glargine 300 U/mL injection pen. It depicts one hand holding the pen and the other hand twisting the pen cap to remove it, with directional arrows indicating the proper twisting motion. A red caution symbol illustrates an incorrect way of handling the pen tip.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 11)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 11)
An instructional illustration depicting two hands preparing an injection device. One hand holds a TOUJEO Max insulin glargine 300 U/mL injection pen, while the other hand is placing or removing a small white cap or cover on a flat surface, likely relating to injection preparation or needle attachment.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 12)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 12)
An instructional illustration showing a hand removing a cap from the opening of a vial, with an injection device partially visible to the left. The image likely demonstrates preparing or accessing medication from the vial before injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 13)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 13)
An instructional illustration showing hands adjusting the dose selector on a TOUJEO Max insulin glargine 300 U/mL pen injector. The image highlights the dose dial being turned to the number 2, demonstrating dose setting prior to subcutaneous injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 14)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 14)
An instructional illustration showing a person holding a prefilled syringe for subcutaneous injection. The needle tip is highlighted and a spray of liquid is depicted exiting the needle, emphasizing preparation or priming of the injection device before use.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 15)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 15)
TOUJEO Max 300 Units/mL insulin glargine injection solution in a single-dose pen for subcutaneous use. The image shows a pen-style injector labeled with dosage marks up to 300 units, a green and white color scheme, and the Sanofi-Aventis U.S. LLC branding. The pen is designed for administering insulin.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 16)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 16)
An instructional illustration showing a hand holding a TOUJEO Max insulin glargine injection pen, with the other hand twisting the dose selector knob upward to adjust or remove the cap. The pen is green and labeled with dose markings, demonstrating the correct handling of the subcutaneous injection device.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 17)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 17)
A close-up image showing the dosage selector dial on a TOUJEO Max insulin glargine injection pen. The dial displays dose numbers including 28 and 30 units, highlighting the adjustable dose delivery feature of the 300 U/mL subcutaneous injection pen by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 18)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 18)
Illustration of a dial with dosage numbers, showing the numbers 28 and 30 on the dial display. This image is likely a close-up detail of a dose-setting mechanism on an injection pen for precise measurement.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 19)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 19)
An instructional illustration showing a hand holding a TOUJEO Max insulin glargine injection pen. The image highlights proper grip and an arrow indicates the direction for pressing or injection, demonstrating how to use the subcutaneous injection device.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 20)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 20)
An instructional illustration showing the proper grip and finger positioning for holding an injection pen, specifically the TOUJEO Max insulin glargine injection pen. The image highlights correct thumb placement on the green dial and the turning direction with an arrow, emphasizing avoiding incorrect thumb positioning shown in a red circle.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 21)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 21)
An instructional illustration showing a hand holding a Toujeo Max injection pen for subcutaneous use. The image highlights holding the pen at the injection site on the skin and includes a close-up inset indicating to hold for 5 seconds after injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 22)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 22)
An instructional diagram showing hands holding an insulin injection pen labeled TOUJEO Max, with a blue arrow indicating the removal of the pen cap from the needle end. The dose window on the pen displays a scale from 50 to 200 units.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 23)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 23)
An instructional illustration showing hands preparing a cartridge-style injectable device by twisting and pushing parts. The device contains a green cartridge with dosage markings, indicating a step to prime or prepare for injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 24)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 24)
An instructional illustration showing how to open a vial by removing the protective cap. One hand holds the vial while the other hand lifts the cap away from the vial neck.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 25)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 25)
An instructional illustration showing two hands demonstrating the removal of a TOUJEO Max insulin glargine 300 U/mL injection pen cap. One hand holds the pen while the other hand pulls the cap off in the direction indicated by a blue arrow.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 26)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 26)
An anatomical illustration showing recommended subcutaneous injection sites for TOUJEO Max (insulin glargine) on the human body. Highlighted injection areas include the upper arms, stomach, and thighs, indicated with green shaded regions and labeled accordingly.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 27)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 27)
An instructional diagram of the TOUJEO Max SoloStar insulin glargine injection pen showing labeled parts: pen cap, cartridge holder with insulin scale (up to 900 units), rubber seal, plunger, dose window, dose pointer, dose selector, injection button, and the insulin name on the cartridge label indicating 300 units/ml strength for subcutaneous injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 28)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 28)
The image shows the labeling of a TOUJEO Max SoloStar insulin glargine injection pen. The label indicates it is for subcutaneous injection with a concentration of 300 units per milliliter (U-300). The label specifies use for a single patient and instructions to adjust by 2 units. The pen is manufactured by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 29)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 29)
The image shows a TOUJEO Max insulin glargine injection pen with strength 300 U/mL. The pen is beige with a patterned green label near the top and a white cap with a green tip. The label area includes a lot number (123XY) and an expiration date (2029-10-31). This product is labeled by Sanofi-Aventis U.S. LLC for subcutaneous use.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 30)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 30)
An instructional illustration showing how to remove the cover from a TOUJEO Max injection pen. The image depicts a hand holding the insulin glargine pen and pulling the cap off in the direction indicated by a blue arrow.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 31)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 31)
Illustration of a TOUJEO Max insulin glargine 300 U/mL injection pen showing a close-up of the dose window area and part of the pen body with labeling indicating the 300 Units/mL concentration.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 32)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 32)
Illustration showing a person using a cloth or tissue to wipe or clean the threaded tip of an injection pen device for subcutaneous administration, consistent with the use of an insulin pen such as TOUJEO Max (insulin glargine) injection solution.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 33)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 33)
Illustration showing hands preparing a vial or an injection pen by removing or adjusting a cap or seal, likely related to subcutaneous injection preparation for Toujeo Max insulin glargine 300 U/mL.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 34)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 34)
Instructional illustration showing hands preparing a TOUJEO Max insulin glargine injection pen. The image depicts removing the cap by twisting it counterclockwise, with a caution inset indicating not to twist a certain part marked with red arrows and a prohibition symbol.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 35)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 35)
An instructional illustration showing a hand holding a TOUJEO Max injection pen filled with insulin glargine 300 U/mL solution, and another hand removing or placing the pen cap. The image demonstrates the handling or preparation step for subcutaneous injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 36)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 36)
An instructional illustration showing a hand removing a cap or seal from a container, with an insulin glargine injection pen partially visible on the left. The image indicates preparation steps for subcutaneous injection of Toujeo Max 300 U/mL insulin glargine.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 37)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 37)
An instructional illustration showing hands adjusting the dose selector on a TOUJEO Max insulin glargine injection pen. The dial display zooms in to indicate a dose of 4 units selected, demonstrating step-by-step dose setting on the subcutaneous injection device.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 38)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 38)
An instructional illustration showing the proper technique for priming a TOUJEO Max 300 U/mL insulin glargine injection pen. The image depicts hands holding the pen, with a close-up of the needle tip expelling a drop of insulin solution, indicating readiness for subcutaneous injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 39)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 39)
TOUJEO Max SoloStar pen for insulin glargine injection, 300 Units/mL, subcutaneous use. The pen has a white body with a label displaying the brand and generic names, strength, dosage form, and manufacturer Sanofi-Aventis U.S. LLC. Dosing increments adjust by 2 units, with a 300 unit dose selector window visible on the pen.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 40)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 40)
An instructional illustration showing how to adjust the dose on a TOUJEO Max SoloStar insulin glargine injection pen. A hand is gripping the pen while the other hand is turning the dose selector dial marked with units, demonstrating dose adjustment by 2 units increments.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 41)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 41)
An illustration showing a close-up view of the dose selector window on the TOUJEO Max insulin pen, highlighting dialed dose numbers used to set the insulin injection dose.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 42)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 42)
Close-up image of a dosing window on a TOUJEO Max insulin glargine injection pen showing a selected dose between 56 and 60 units. The pen is designed for subcutaneous injection of 300 U/mL solution. The image highlights the dose adjustment feature of the pen.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 43)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 43)
An instructional illustration showing a hand holding a TOUJEO Max insulin glargine injection pen. The index finger is positioned to push the injection button, indicated by a blue arrow pointing left, demonstrating how to administer the subcutaneous injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 44)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 44)
Instructional diagram showing proper use of the dosing dial on the TOUJEO Max insulin glargine 300 U/mL injection pen by Sanofi-Aventis. It illustrates holding the dial with the thumb pressing the green button correctly, with a magnified view indicating the proper finger placement, and a red alert marking the incorrect thumb positioning.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 45)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 45)
An instructional illustration showing the proper technique for using an injectable pen device for insulin glargine injection. It depicts a hand holding the pen against the skin and highlights a close-up of the pen tip with an instruction to hold for 5 seconds after injection.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 46)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 46)
An instructional diagram showing a hand holding a TOUJEO Max insulin glargine injection pen with a dose scale visible, indicating units from 100 to 900. Another hand is shown removing the protective cap from the needle, with a blue arrow indicating the direction to pull the cap off the injection pen needle.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 47)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 47)
An instructional diagram illustrating how to operate the TOUJEO Max insulin glargine 300 U/mL pen injector. It shows a hand twisting the dose selector on the pen with arrows indicating the direction to turn, and another hand pressing the dose button to administer the injection subcutaneously.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 48)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 48)
An instructional illustration shows hands removing a gray foil seal from a bottle and holding a white stopper or cap above the bottle opening, indicating a step in preparing or opening the container.*
FDA Label Image

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 49)

Figure (C9561d96 124d 48ca 982f 0aa1575bff36 49)
An instructional diagram showing a hand loading a Toujeo Max insulin glargine injection pen by attaching the insulin cartridge to the pen body, indicated by a blue arrow pointing right. This diagram supports proper assembly of the subcutaneous injection device.*
FDA Label Image

Principal Display Panel (1.5 mL Pen Carton)

Principal Display Panel (1.5 mL Pen Carton)
Packaging label for TOUJEO SoloStar insulin glargine injection, 300 units/mL (U-300) strength. The label shows a disposable prefilled pen insulin delivery device for subcutaneous use, manufactured by Sanofi-Aventis U.S. LLC. The carton indicates it contains three 1.5 mL prefilled pens, with storage and usage instructions printed on the label.*
FDA Label Image

Principal Display Panel (3 mL Pen Carton)

Principal Display Panel (3 mL Pen Carton)
Packaging label for TOUJEO Max SoloStar (insulin glargine) injection, 300 units/mL (U-300) solution for subcutaneous use. The label highlights that it is for single patient use only, adjusts by 2 units, and contains two 3 mL prefilled pens. The product is manufactured by Sanofi-Aventis U.S. LLC and includes instructions on storage and usage precautions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.